1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections

Abstract

Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed.

1 . A compound of Formula (I) 
       
         
           
           
               
               
           
         
       
       or a stereoisomer or a pharmaceutically acceptable salt thereof;
 wherein: 
 R 1  is:
 (a) SO 3 M, 
 (b) SO 2 NH 2 , 
 (c) PO 3 M, 
 (d) CH 2 COOM, 
 (e) CF 2 COOM, 
 (f) CHFCOOM, or 
 (g) CF 3 ; 
 
 M is hydrogen or a cation; 
 R 2  is:
 (a) hydrogen, 
 (b) (CH 2 ) n —R 3 , or 
 (c) COOR 3 , 
 
 n is 0, 1 or 2; 
 R 3  is:
 (a) hydrogen, 
 (b) C 1 -C 6  alkyl optionally substituted with one or more substituents independently selected from halogen, OR 5 , CN, COOR 5 , CONR 6 R 7 , NR 6 R 7 , NR 5 COR 8 , NR 5 CONR 6 R 7 , heterocyclyl, heteroaryl, cycloalkyl or aryl, 
 (c) CN, 
 (d) NR 6 R 7 , 
 (e) CONR 6 R 7 , 
 (f) NHCONR 6 R 7 , 
 (g) aryl optionally substituted with one or more substituents independently selected from C 1 -C 6  alkyl, OR 5 , NR 6 R 7 , halogen, CN, CONR 6 R 7 , SO 2 -alkyl, SO 2 -aryl, OSO 2 -alkyl, OSO 2 -aryl, or NHCONR 6 R 7 , 
 (h) heterocyclyl optionally substituted with one or more substituents independently selected from C 1 -C 6  alkyl, OR 5 , NR 6 R 7 , halogen, CN, CONR 6 R 7 , SO 2 -alkyl, SO 2 -aryl, OSO 2 -alkyl, OSO 2 -aryl, or NHCONR 6 R 7 , 
 (i) heteroaryl optionally substituted with one or more substituents independently selected from C 1 -C 6  alkyl, OR 5 , NR 6 R 7 , halogen, CN, CONR 6 R 7 , SO 2 -alkyl, SO 2 -aryl, OSO 2 -alkyl, OSO 2 -aryl, or NHCONR 6 R 7 , 
 (j) cycloalkyl optionally substituted with one or more substituents independently selected from C 1 -C 6  alkyl, OR 5 , NR 6 R 7 , halogen, CN, CONR 6 R 7 , SO 2 -alkyl, SO 2 -aryl, OSO 2 -alkyl, OSO 2 -aryl, or NHCONR 6 R 7 , 
 (k) cycloalkyl substituted with C 1 -C 6  alkyl wherein C 1 -C 6  alkyl is further substituted with one or more substituents independently selected from OR 5 , NR 6 R 7 , halogen, CN, or CONR 6 R 7 , or 
 (l) OR 8 ; 
 
 R 4  is:
 (a) hydrogen, 
 (b) C 1 -C 6  alkyl optionally substituted with one or more substituents independently selected from halogen, OR 5 , CN, COOR 5 , CONR 6 R 7 , NR 6 R 7 , NR 5 COR 8 , heterocyclyl, heteroaryl, cycloalkyl or aryl, 
 (c) aryl optionally substituted with one or more substituents independently selected from C 1 -C 6  alkyl, OR 5 , NR 6 R 7 , halogen, CN, CONR 6 R 7 , SO 2 -alkyl, SO 2 -aryl, OSO 2 -alkyl, OSO 2 -aryl, or NHCONR 6 R 7 , 
 (d) heterocyclyl optionally substituted with one or more substituents independently selected from C 1 -C 6  alkyl, OR 5 , NR 6 R 7 , halogen, CN, CONR 6 R 7 , SO 2 -alkyl, SO 2 -aryl, OSO 2 -alkyl, OSO 2 -aryl, or NHCONR 6 R 7 , 
 (e) heteroaryl optionally substituted with one or more substituents independently selected from C 1 -C 6  alkyl, OR 5 , NR 6 R 7 , halogen, CN, CONR 6 R 7 , SO 2 -alkyl, SO 2 -aryl, OSO 2 -alkyl, OSO 2 -aryl, or NHCONR 6 R 7 , or 
 (f) cycloalkyl optionally substituted with one or more substituents independently selected from C 1 -C 6  alkyl, OR 5 , NR 6 R 7 , halogen, CN, CONR 6 R 7 , SO 2 -alkyl, SO 2 -aryl, OSO 2 -alkyl, OSO 2 -aryl, or NHCONR 6 R 7 ; 
 
 R 5  and R 8  are each independently:
 (a) hydrogen, or 
 (b) C 1 -C 6  alkyl optionally substituted with one or more substituents independently selected from halogen, CN, CONR 6 R 7 , NR 6 R 7 , heterocyclyl, heteroaryl, cycloalkyl or aryl; 
 
 R 6  and R 7  are each independently:
 (a) hydrogen, 
 (b) C 1 -C 6  alkyl optionally substituted with one or more substituents independently selected from halogen, OR 5 , CN, COOR 5 , CONR 5 R 8 , NR 5 R 8 , NR 5 COR 8 , heterocyclyl, heteroaryl, cycloalkyl or aryl, 
 (c) aryl optionally substituted with one or more substituents independently selected from C 1 -C 6  alkyl, OR 5 , NR 5 R 8 , halogen, CN, CONR 5 R 8 , SO 2 -alkyl, SO 2 -aryl, OSO 2 -alkyl, OSO 2 -aryl, or NHCONR 5 R 8 , 
 (d) heterocyclyl optionally substituted with one or more substituents independently selected from C 1 -C 6  alkyl, OR 5 , NR 5 R 8 , halogen, CN, CONR 5 R 8 , SO 2 -alkyl, SO 2 -aryl, OSO 2 -alkyl, OSO 2 -aryl, or NHCONR 5 R 8 , 
 (e) heteroaryl optionally substituted with one or more substituents independently selected from C 1 -C 6  alkyl, OR 5 , NR 5 R 8 , halogen, CN, CONR 5 R 8 , SO 2 -alkyl, SO 2 -aryl, OSO 2 -alkyl, OSO 2 -aryl, or NHCONR 5 R 8 , 
 (f) cycloalkyl optionally substituted with one or more substituents independently selected from C 1 -C 6  alkyl, OR 5 , NR 5 R 8 , halogen, CN, CONR 5 R 8 , SO 2 -alkyl, SO 2 -aryl, OSO 2 -alkyl, OSO 2 -aryl, or NHCONR 5 R 8 , or 
 (g) R 6  and R 7  are joined together to form a four to seven member ring. 
 
 
     
     
         2 . A compound according  claim 1 , selected from:
 (2S,5R)-7-oxo-N-[(2S)-pyrrolidin-2-ylmethyloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S,5R)-7-oxo-N-[(2R)-pyrrolidin-2-ylmethyloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S,5R)-7-oxo-N-[(3S)-pyrrolidin-3-ylmethyloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S,5R)-7-oxo-N-[(3R)-pyrrolidin-3-ylmethyloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S,5R)-N-{[(2S,4R)-4-hydroxyl-pyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-{[(2S,4R)-4-cyano-pyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-{[(5R)-5-cyanopyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-{[(SR)-5-cyanopyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-{[(2S,4R)-4-trifluoroacetylamino-pyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-{[(2S)-1-carbamimidoyl-pyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S ,5R)-7-oxo-N-{1-[(2S)-pyrrolidin-2-yl]ethyloxy }-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S ,5R)-7-oxo-N-{[(2S)-5-oxopyrrolidin-2-yl]methyloxy}-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S ,5R)-N-[(2S)-azetidin-2-ylmethyloxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S ,5R)-N-[(2R)-azetidin-2-ylmethyloxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S ,5R)-7-oxo-N-(piperidin-4-ylmethyloxy)-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S ,5R)-7-oxo-N-((3R,S)piperidin-3-ylmethyloxy)-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S ,5R)-7-oxo-N-((2R,S)piperidin-2-ylmethyloxy)-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S ,5R)-7-oxo-N-((2S)piperidin-2-ylmethyloxy)-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S ,5R)-7-oxo-N-((2S)piperidin-2-ylmethyloxy)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S ,5R)-7-oxo-N-{1-[(2S)-piperidin-2-yl]ethyloxy}-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S ,5R)-N-(azepan-2-ylmethyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S)-N-(2,3-dihydro-1H-indol-2-ylmethyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S ,5R)-N-{[(2R,S)-1,2,3 ,4-tetrahydro-quinolin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S ,5R)-N-{[(3 S)-1,2,3,4-tetrahydro-isquinolin-3-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S ,5R)-N-{[(4S)-1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-4-yl]methoxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S ,5R)-N-{[(4S)-1H-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-4-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S)-N-1(4,5-dihydroxy-1,4-dihydropyridin-2-yl)methyloxyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S ,5R)-7-oxo-N-{[(4S)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-oxazol-4-yl] methyloxy}-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-7-oxo-N-{[(4S)-2-((2S)-pyrrolidin-2-yl)-4,5-dihydro-1,3-oxazol-4-yl]methyloxy}-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-7-oxo-N-[(3R,S)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-7-oxo-N-[(3S)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane -2-carboxamide;   (2S,5R)-7-oxo-N-[(3R)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-{[(3R,5S)-5-cyanopyrrolidin-3-yl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   (2S,5R)-N-{[(3S,5S)-5-cyanopyrrolidin-3-yl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S ,5R)-N-{[(3R,5S)-5-carbamoylpyrrolidin-3-yl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-(azetidin-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-methyloxy-7-oxo-N-(piperidin-2-ylmethyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-methyloxy-7-oxo-N-(piperidin-3-ylmethyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-methyloxy-7-oxo-N-(pyrrolidin-2-ylmethyl)-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-[(2S)-azetidin-2-ylmethyl]-N-hydroxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-hydroxy-7-oxo-N-[(2S)-pyrrolidin-2-ylmethyl]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-hydroxy-7-oxo-N-[(2S)-piperidin-2-ylmethyl]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-[(2S)-azepan-2-ylmethyl]-N-hydroxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-[(2R)-azetidin-2-ylmethyl]-N-hydroxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-hydroxy-7-oxo-N-[(2R)-pyrrolidin-2-ylmethyl]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-hydroxy-7-oxo-N-[(2R)-piperidin-2-ylmethyl]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   (2S,5R)-N-[(2R)-azepan-2-ylmethyl]-N-hydroxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   or a stereoisomer or a pharmaceutically acceptable salt thereof.   
     
     
         3 . A compound according  claim 1 , selected from:
 Sodium salt of (2S ,5R)-7-oxo-N-[(2S)-pyrrolidin-2-ylmethyloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-7-oxo-N-[(2R)-pyrrolidin-2-ylmethyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-7-oxo-N-[(35)-pyrrolidin-3-ylmethyloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-7-oxo-N-[(3R)-pyrrolidin-3-ylmethyloxy]-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-{[(2S,5R)-4-hydroxyl-pyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-N-{[(2S ,4R)-4-cyanol-pyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2. 1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-N-{[(5R)-5-cyanopyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2. 1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-{[(SR)-5 -cyanopyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-N-{[(2S ,4R)-4-trifluoroacetylamino-pyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-N-{[(2S)-1 -carbamimidoyl-pyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2 1]octane-2-carboxamide;   Sodium salt of (2S,5R)-7-oxo-N-{1-[(25)-pyrrolidin-2-yl]ethyloxy}-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-7-oxo-N-{[(2S)-5-oxopyrrolidin-2-yl]methyloxy}-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-[(25)-azetidin-2-ylmethyloxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-[(2R)-azetidin-2-ylmethyloxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-7-oxo-N-(piperidin-4-ylmethyloxy)-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-7-oxo-N-((3R,S)-piperidin-3-ylmethyloxy)-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-7-oxo-N-((2R,S)piperidin-2-ylmethyloxy)-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-7-oxo-N-((2S)piperidin-2-ylmethyloxy)-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-7-oxo-N-((2S)piperidin-2-ylmethyloxy)-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-7-oxo-N-{1-[(2S)-piperidin-2-yl]ethyloxy}-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-(azepan-2-ylmethyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2. 1]octane-2-carboxamide;   Sodium salt of (2S)-N-(2,3-dihydro-1H-indol-2-ylmethyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2. 1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-{[(2R,S)-1,2,3,4-tetrahydro-quinolin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-N-{[(3S)-1,2,3,4-tetrahydro-isquinolin-3-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-{[(4S)-1-methyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-4-yl]methoxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-{[(4S)-1H-1,4,5,6-tetrahydropyrrolo[3 ,4-c]pyrazol-4-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   Sodium salt of (2S)-N-[(4,5-dihydroxy-1,4-dihydropyridin-2-yl)methyloxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-7-oxo-N-{[(4S)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-oxazol-4-yl]methyloxy}-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-7-oxo-N-{[(4S)-2-(2S)-pyrrolidin-2-yl)-4,5-dihydro-1,3-oxazol-4-yl]methyloxy}-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-7-oxo-N-[(3R,S)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-7-oxo-N-[(3S)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-7-oxo-N-[(3R)-pyrrolidin-3-yloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-N-{[(3R,5R)-5-cyanopyrrolidin-3-yl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-{[(3S ,5S)-5-cyanopyrrolidin-3-yl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2. 1 ]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-{[(3R,5R)-5-carbamoylpyrrolidin-3-yl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-(azetidin-3-yloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-methyloxy-7-oxo-N-(piperidin-2-ylmethyl)-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-methyloxy-7-oxo-N-(piperidin-3-ylmethyl)-6-(sulfooxy)-1 ,6-diazabicyclo [3.2.1 ]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-methyloxy-7-oxo-N-(pyrrolidin-2-ylmethyl)-6-(sulfooxy)-1,6-diazabicyclo [3.2.1 ]octane-2-carboxamide;   (2S,5R)-N-(2-aminoethyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide trifluoroacetic acid salt;   (2S,5R)-N-(2-carbamimidamidoethyloxy)-7-oxo-6-(sulfooxy)-1,6-diaz abicyclo [3.2.1]octane-2-carboxamide trifluoroacetic acid salt;   (2S,5R)-N-(3-aminopropyloxy)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide trifluoroacetic acid salt;   (2S,5R)-N-{[(2S)-2,5-diaminopentyl]oxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide trifluoroaceticacid salt;   (2S,5R)-N-{[(2S,4R)-4-aminopyrrolidin-2-yl]methyloxy}-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide trifluoroacetic acid salt;   (2S,5R)-7-oxo-N-[(25)-piperazin-2-ylmethyloxy]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide trifluoroaceticacid salt;   (2S,5R)-N-methyloxy-7-oxo-N-(piperazin-2-ylmethyl)-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide trifluoroaceticacid salt;   Sodium salt of (2S,5R)-N-methoxy-N-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium Salt of (2S ,5R)-N-methoxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-hydroxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   Sodium salt of (2S ,5R)-N-[(1-methyl-1H-pyrazol-5-yl)methyloxy]-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-hydroxy-N-methyl-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1 ]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-[(2S)-azetidin-2-ylmethyl]-N-hydroxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-hydroxy-7-oxo-N-[(2S)-pyrrolidin-2-ylmethyl]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-hydroxy-7-oxo-N-[(2S)-piperidin-2-ylmethyl]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-[(25)-azepan-2-ylmethyl]-N-hydroxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1 ]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-[(2R)-azetidin-2-ylmethyl]-N-hydroxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-hydroxy-7-oxo-N-[(2R)-pyrrolidin-2-ylmethyl]-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-hydroxy-7-oxo-N-[(2R)-piperidin-2-ylmethyl]-6-(sulfooxy)-1,6-diazabicyclo [3.2. 1]octane-2-carboxamide;   Sodium salt of (2S,5R)-N-[(2R)-azepan-2-ylmethyl]-N-hydroxy-7-oxo-6-(sulfooxy)-1,6-diazabicyclo [3.2.1]octane-2-carboxamide;   or a stereoisomer thereof.   
     
     
         4 . A pharmaceutical composition comprising a compound according to any of the  claims 1  to  3 . 
     
     
         5 . A method for preventing or treating bacterial infection in a subject, said method comprising administering to said subject a pharmaceutically effective amount of a compound according to any of the  claims 1  to  3 . 
     
     
         6 . A method for preventing or treating a bacterial infection in a subject, said infection being caused by bacteria producing one or more beta-lactamase enzymes, wherein the method comprises administering to said subject a pharmaceutically effective amount of a compound according to any of the  claims 1  to  3 . 
     
     
         7 . A pharmaceutical composition according to  claim 4 , further comprising at least one beta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanic acid, or a pharmaceutically acceptable derivative thereof. 
     
     
         8 . A pharmaceutical composition according to  claim 4  or  7 , further comprising at least one antibacterial agent or a pharmaceutically acceptable derivative thereof. 
     
     
         9 . A method for preventing or treating bacterial infection in a subject, said method comprising administering to said subject a pharmaceutically effective amount of a pharmaceutical composition according to  claim 4 ,  7  or  8 . 
     
     
         10 . A method for preventing or treating a bacterial infection in a subject, said infection being caused by bacteria producing one or more beta-lactamase enzymes, wherein the method comprises administering to said subject a pharmaceutically effective amount of a pharmaceutical composition according to  claim 4 ,  7  or  8 . 
     
     
         11 . A method for preventing or treating a bacterial infection in a subject, said method comprising administering to said subject a pharmaceutically effective amount of: (a) a compound of Formula (I) according to  claim 1  or a stereoisomer or a pharmaceutically acceptable salt thereof, and (b) at least one beta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanic acid, or a pharmaceutically acceptable derivative thereof. 
     
     
         12 . A method for preventing or treating a bacterial infection in a subject, said infection being caused by bacteria producing one or more beta-lactamase enzymes, said method comprising administering to said subject a pharmaceutically effective amount of: (a) a compound of Formula (I) according to  claim 1  or a stereoisomer or a pharmaceutically acceptable salt thereof, and (b) at least one beta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanic acid, or a pharmaceutically acceptable derivative thereof. 
     
     
         13 . A method for preventing or treating a bacterial infection in a subject, said method comprising administering to said subject a pharmaceutically effective amount of: (a) a compound of Formula (I) according to  claim 1  or a stereoisomer or a pharmaceutically acceptable salt thereof, and (b) at least one antibacterial agent or a pharmaceutically acceptable derivative thereof. 
     
     
         14 . A method for preventing or treating a bacterial infection in a subject, said infection being caused by bacteria producing one or more beta-lactamase enzymes, said method comprising administering to said subject a pharmaceutically effective amount of: (a) a compound of Formula (I) according to  claim 1  or a stereoisomer or a pharmaceutically acceptable salt thereof, and (b) at least one antibacterial agent or a pharmaceutically acceptable derivative thereof. 
     
     
         15 . A method for preventing or treating a bacterial infection in a subject, said method comprising administering to said subject a pharmaceutically effective amount of: (a) a compound of Formula (I) according to  claim 1  or a stereoisomer or a pharmaceutically acceptable salt thereof; (b) at least one beta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanic acid, or a pharmaceutically acceptable derivative thereof, and (c) at least one antibacterial agent or a pharmaceutically acceptable derivative thereof. 
     
     
         16 . A method for preventing or treating a bacterial infection in a subject, said infection being caused by bacteria producing one or more beta-lactamase enzymes, said method comprising administering to said subject a pharmaceutically effective amount of: (a) a compound of Formula (I) according to  claim 1  or a stereoisomer or a pharmaceutically acceptable salt thereof, (b) at least one beta-lactamase inhibitor selected from sulbactam, tazobactam, clavulanic acid, or a pharmaceutically acceptable derivative thereof, and (c) at least one antibacterial agent or a pharmaceutically acceptable derivative thereof. 
     
     
         17 . A method for increasing antibacterial effectiveness of a antibacterial agent in a subject, said method comprising co-administering said antibacterial agent or a pharmaceutically acceptable derivative thereof with a pharmaceutically effective amount of a compound of Formula (I) according to  claim 1 , or a stereoisomer or a pharmaceutically acceptable salt thereof. 
     
     
         18 . A pharmaceutical composition according to  claim 8  or a method according to any of the  claim 9 ,  10 ,  13 ,  14 ,  15 ,  16  or  17 , wherein the antibacterial agent is selected from a group consisting of aminoglycosides, ansamycins, carbacephems, cephalosporins, cephamycins, lincosamides, lipopeptides, macrolides, monobactams, nitrofurans, penicillins, polypeptides, quinolones, sulfonamides, tetracyclines, or oxazolidinone antibacterial agents. 
     
     
         19 . A pharmaceutical composition according to  claim 8  or a method according to any of the  claim 9 ,  10 ,  13 ,  14 ,  15 ,  16  or  17 , wherein the antibacterial agent is a beta-lactam antibacterial agent. 
     
     
         20 . A pharmaceutical composition according to  claim 8  or a method according to any of the  claim 9 ,  10 ,  13 ,  14 ,  15 ,  16  or  17 , wherein said antibacterial agent is selected from a group consisting of penicillins, penems, carbapenems, cephalosporins, and monobactams. 
     
     
         21 . A pharmaceutical composition according to  claim 8  or a method according to any of the  claim 9 ,  10 ,  13 ,  14 ,  15 ,  16  or  17 , wherein the antibacterial agent is a cephalosporin antibiotic selected from a group consisting of cephalothin, cephaloridine, cefaclor, cefadroxil, cefamandole, cefazolin, cephalexin, cephradine, ceftizoxime, cefoxitin, cephacetrile, cefotiam, cefotaxime, cefsulodin, cefoperazone, ceftizoxime, cefmenoxime, cefmetazole, cephaloglycin, cefonicid, cefodizime, cefpirome, ceftazidime, ceifriaxone, cefpiramide, cefbuperazone, cefozopran, cefepime, cefoselis, cefluprenam, cefuzonam, cefpimizole, cefclidin, cefixime, ceftibuten, cefdinir, cefpodoxime axetil, cefpodoxime proxetil, cefteram pivoxil, cefetamet pivoxil, cefcapene pivoxil or cefditoren pivoxil, cefuroxime, cefuroxime axetil, loracarbacef, ceftaroline and latamoxef. 
     
     
         22 . A pharmaceutical composition according to  claim 8  or a method according to any of the  claim 9 ,  10 ,  13 ,  14 ,  15 ,  16  or  17 , wherein the antibacterial agent is selected from a group consisting of ceftazidime, cefepime, cefpirome, piperacillin doripenem, meropenem, imipenem, ceftaroline and ceftolozane. 
     
     
         23 . A pharmaceutical composition according to  claim 8  or a method according to any of the  claim 9 ,  10 ,  13 ,  14 ,  15 ,  16  or  17 , wherein the antibacterial agent is selected from a group consisting of aminoglycosides, ansamycins, carbacephems, cephalosporins, cephamycins, lincosamides, lipopeptides, macrolides, monobactams, nitrofurans, penicillins, polypeptides, quinolones, sulfonamides, tetracyclines, or oxazolidinone antibacterial agents.